These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29402706)

  • 21. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
    Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
    Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
    Keizman D; Ish-Shalom M; Huang P; Eisenberger MA; Pili R; Hammers H; Carducci MA
    Eur J Cancer; 2012 Jan; 48(2):202-8. PubMed ID: 22018713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
    Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
    Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
    J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab.
    Yoshimura A; Nagahara A; Ishizuya Y; Yamamoto Y; Hatano K; Kawashima A; Nakai Y; Nakayama M; Nishimura K; Nonomura N; Kato T
    Clin Exp Med; 2024 May; 24(1):111. PubMed ID: 38780659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
    Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
    Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
    Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
    Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement of changes in serum-based inflammatory indicators to monitor response to nivolumab monotherapy in advanced gastric cancer: a multicenter retrospective study.
    Inukai M; Nishi T; Matsuoka H; Matsuo K; Suzuki K; Serizawa A; Akimoto S; Nakauchi M; Tanaka T; Kikuchi K; Shibasaki S; Uyama I; Suda K
    BMC Cancer; 2024 Sep; 24(1):1121. PubMed ID: 39251991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ueda K; Suekane S; Kurose H; Ogasawara N; Hiroshige T; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
    Jpn J Clin Oncol; 2022 Feb; 52(2):179-186. PubMed ID: 34607361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.
    Santagata S; Trotta AM; D'Alterio C; Napolitano M; Rea G; Di Napoli M; Portella L; Ieranò C; Guardascione G; Coppola E; Caux C; Dubois B; Boyle HJ; Carles J; Rossetti S; Azzaro R; Feroce F; Perdonà S; Fordellone M; Bello AM; Califano D; Chiodini P; Pignata S; Scala S
    Clin Cancer Res; 2024 Oct; 30(20):4755-4767. PubMed ID: 39167621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.
    Ota Y; Takahari D; Suzuki T; Osumi H; Nakayama I; Oki A; Wakatsuki T; Ichimura T; Ogura M; Shinozaki E; Suenaga M; Chin K; Yamaguchi K
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):265-272. PubMed ID: 31907646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab.
    Nakayama T; Takeshita H; Kagawa M; Washino S; Shirotake S; Miura Y; Hyodo Y; Izumi K; Inoue M; Matsuoka Y; Miyagawa T; Oyama M; Saito K; Kawakami S
    Int J Clin Oncol; 2024 Oct; 29(10):1528-1537. PubMed ID: 39046676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma.
    Aslan V; Karabörk Kılıç AC; Özet A; Üner A; Günel N; Yazıcı O; Savaş G; Bayrak A; Eraslan E; Öksüzoğlu B; Kılıç HK; Özdemir N
    BMC Cancer; 2023 Oct; 23(1):1045. PubMed ID: 37904131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.